12.25
-3.54%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xbrane Biopharma
Its shares trade on Nasdaq Stockholm under the ticker XBRANE.ST. It has been listed since 3 February 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 152.4m and net income of SEK 127.2m. At that date it held total assets of SEK 671.6m and shareholders' equity of SEK 560.7m.
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2016
- Employees
- 92
- Website
- xbrane.com ↗
Leadership
Pay as last reported
- Mr. Anders TullgrenIndependent Chairman of the BoardSEK 773,000
- Mr. Martin AmarkChief Executive OfficerSEK 3.4m
- Mr. Siavash BashiriDeputy Chief Executive Officer, Head - BiosimilarsSEK 1.8m
- Ms. Jane BenyamiActing Chief Financial Officer
- Dr. David VikstroemChief Technology OfficerSEK 449,008
- Ms. Dina JurmanHead - Clinical Affairs
- Mr. Anders WallstroemHead - Manufacturing and Supply Chain
- Mr. Kristoffer BissessarIndependent DirectorSEK 299,000
- Ms. Kirsti GjellanIndependent DirectorSEK 378,000
- Ms. Eva NilsagardIndependent DirectorSEK 471,000
- Mr. Mats ThorenIndependent DirectorSEK 412,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 50
- Social
- 45
- Governance
- 79
- Direct emissions (scope 1)
- 0 t
- Energy emissions (scope 2)
- 10 t
- Women in the workforce
- 61%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xbrane Biopharma AB develops Sperotide for Decapeptyl, Trelstar, and Pamorelin.
- Xbrane Biopharma AB manufactures Xlucane as a biosimilar to Lucentis.
- Xbrane Biopharma AB employs 92 full-time employees in Solna, Stockholm.
Weaknesses
- Xbrane Biopharma AB has no products in the Financials sector.
- Xbrane Biopharma AB's business is limited to Health Care biotechnology.
- Xbrane Biopharma AB's IPO was on 3 February 2016.
Opportunities
- Xbrane Biopharma AB can expand into the Information Technology sector.
- Xbrane Biopharma AB can target the Consumer Discretionary segment.
- Xbrane Biopharma AB can enter the German market for biosimilars.
Threats
- Xbrane Biopharma AB faces competition from other Health Care companies.
- Xbrane Biopharma AB must comply with Health Care regulations.
- Xbrane Biopharma AB's products are subject to market volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.